Insulet (PODD) 2024 Wells Fargo Healthcare Conference summary

Business performance and financial outlook

• Raised guidance for 2024: top-line growth of 16%-19%, gross margin at 69%, and 14% operating margin, reflecting accelerating core business and confidence in future growth.

• Margin expansion is expected to continue, driven by scale, manufacturing improvements, and international pricing, with 100 basis points as a floor for annual operating margin growth.

• Gross margin target of 70% is not a ceiling; future expansion will be more gradual and driven by volume and operational efficiency, including benefits from the new Malaysia plant.

• Free cash flow positive and growing, supporting ongoing innovation and shareholder returns.

Type 2 diabetes market expansion

• Early approval for Omnipod 5 in Type 2 diabetes opens a market of 2.5 million insulin-intensive patients, with current penetration under 5%.

• Launch strategy focuses first on existing call points and direct-to-consumer channels, with sales force expansion planned for 2025.

• Coverage for Omnipod 5 in Type 2 is strong, with only minor adjustments needed.

• Clinical data from the SECURE-T2D trial shows significant insulin reduction and improved outcomes for both basal and basal-bolus patients.

• New customer starts are expected to grow sequentially through 2024, with the financial impact of Type 2 ramping in 2025.

Product innovation and competitive landscape

• Omnipod 5 maintains a leadership position despite increased competition, with sequential growth even as new competitors enter the market.

• Upcoming catalysts include G7 and Libre 2+ sensor integrations, iOS app launch, and further international expansion.

• Product differentiation includes automated insulin delivery, sensor choice, and strong clinical evidence, with ongoing investment in R&D and clinical trials.

• New competitors are not seen as a threat due to Omnipod 5’s established technology, integration, and user experience.